Vyhláška, kterou se mění vyhláška č. 57/1997 Sb., kterou se stanoví léčivé přípravky plně hrazené z veřejného zdravotního pojištění a výše úhrad jednotlivých léčivých látek, ve znění pozdějších předpisů
| 512 | V06DF | náhrady mléka obsahující sojovou bílkovinu | p.o. | ||||
|---|---|---|---|---|---|---|---|
| 512.1 | IV06DF | náhrady mléka obsahující sojovou bílkovinu | p.o. | 100 | GM | 27,96 | L/J11 |
| 513 | V06DX | jiné kombinace přípravků pro výživu | p.o. | ||||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 513.1 | V06DX | MCT olej | p.o. | 100 | ML | 103,13 | L/J11 |
| 513.2 | V06DX | kombinace s vysokým obsahem mléčné bílkoviny a kalcia | p.o. | 100 | GM | 44,87 | L/J11 |
| 514 | V07AB | rozpouštědla a ředidla, včetně irigačních roztoků | parent. | ||||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 514.1 | V07AB | voda pro injekci (do 2 ml v jedné ampuli včetně) | parent. | 1 | ML | 2,69 | |
| 514.2 | V07AB | voda pro injekci (nad 2 do 10 ml v jedné ampuli včetně) | parent. | 10 | ML | 3,32 | |
| 00387 | AQUA PRO INJECTIONE BIOTIKA | inj 10x10ml | BTA | SK | |||
| 00388 | AQUA PRO INJECTIONE BIOTIKA | inj 50x10ml | BTA | SK | |||
| 55807 | AQUA PRO INJECTIONE BIOTIKA | inj 100x10ml | BTA | SK | |||
| 514.3 | V07AB | voda pro injekci nad 10 ml v jedné ampuli nebo lahvi | parent. | 100 | ML | 13,98 | |
| 44559 | STERILE WATER F.INJ.U.S.P.SIFRA | inf 16x250ml | SFR | I | |||
| 31427 | STERILE WATER F.INJ. FRESENIUS | inf 12x500ml | FKI | I | |||
| 44560 | STERILE WATER F.INJ.U.S.P.SIFRA | inf 12x500ml | SFR | I | |||
| 57776 | WATER FOR INJECTIONS BIEFFE | inf 1x1000ml(vak) | BFH | E | |||
| 53363 | AQUA PRO INJECTIONE INFUSIA | sol 1x250ml(sklo) | IHO | CZ | |||
| 57775 | WATER FOR INJECTIONS BIEFFE | inf 1x500ml(vak) | BFH | E | |||
| 57773 | WATER FOR INJECTIONS BIEFFE | inf 1x250ml(vak) | BFH | E | |||
| 92782 | AQUA PRO INJECTIONE MEDIEKOS | sol 1x1000ml(vak) | MKS | CZ | |||
| 31426 | STERILE WATER F.INJ. FRESENIUS | inf 1x500ml | FKI | I | |||
| 43759 | STERILE WATER F.INJ.U.S.P.SIFRA | inf 1x250ml | SFR | I | |||
| 97727 | WATER FOR INJECTIONS BIEFFE | inf 1x500ml(sklo) | BFF | I | |||
| 95566 | STERILE WATER F.INJ.FRESENIUS | par Iqf 20x500ml-pe | FKI | I | |||
| 70528 | AQUA PRO INJECTIONE MEDICAMENTA | inf 1x500ml | MVM | CZ | |||
| 70484 | WATER FOR INJECTIONS BIEFFE | inf 1x1000ml(plast) | BFF | I | |||
| 53364 | AQUA PRO INJECTIONE INFUSIA | sol 1x500ml(sklo) | IHO | CZ | |||
| 43760 | STERILE WATER F.INJ.U.S.P.SIFRA | inf 1x500ml | SFR | I | |||
| 31424 | STERILE WATER F.INJ. FRESENIUS | inf 1x250ml | FKI | I | |||
| 69789 | AQUA PRO INJECTIONE ARDEAPHARMA | inf 1x500ml | ARD | CZ | |||
| 31429 | STERILE WATER F.INJ. FRESENIUS | inf 6x1000ml | FKI | I | |||
| 31428 | STERILE WATER F.INJ. FRESENIUS | inf 1x1000ml | FKI | I | |||
| 91876 | AQUA PRO INJECTIONE INFUSIA | sol 1x500ml | IHO | CZ | |||
| 44557 | STERILE WATER F.INJ.U.S.P.SIFRA | inf 6x1000ml | SFR | I | |||
| 95565 | STERILE WATER F.INJ.FRESENIUS | par Iqf 1x1000ml-pe | FKI | I | |||
| 85557 | WATER FOR INJECTIONS BIEFFE | inf 1x250ml(plast) | BFF | I | |||
| 89244 | AQUA PRO INJECTIONE ARDEAPHARMA | inf 1x250ml | ARD | CZ | |||
| 95564 | STERILE WATER F.INJ.FRESENIUS | par Iqf 1x500ml-pe | FKI | I | |||
| 80486 | AQUA PRO INJECTIONE MEDICAMENTA | inf 1x250ml | MVM | CZ | |||
| 85558 | WATER FOR INJECTIONS BIEFFE | inf 1x500ml(plast) | BFF | I | |||
| 31425 | STERILE WATER F.INJ. FRESENIUS | inf 16x250ml | FKI | I | |||
| 95567 | STERILE WATER F.INJ.FRESENIUS | par Iqf12x1000ml-pe | FKI | I | |||
| 83943 | AQUA PRO INJECTIONE MEDIEKOS | sol 1x500ml(vak) | MKS | CZ | |||
| 43761 | STERILE WATER F.INJ.U.S.P.SIFRA | inf 1x1000ml | SFR | I | |||
| 92783 | AQUA PRO INJECTIONE MEDIEKOS | sol 1x2000ml(vak) | MKS | CZ | |||
| 97726 | WATER FOR INJECTIONS BIEFFE | inf 1x250ml(sklo) | BFF | I | |||
| 515 | V08A | rozpustné nefrotropní RTG kontrastní látky | p.o. | ||||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 515.1 | V08AA05 | kyselina ioxitalamová | p.o. | 10 | ML | 59,19 | K |
| 59497 | TELEBRIX GASTRO | sol 10x100ml/30gm | GUT | F | |||
| 515.2 | V08AB04 | iopamidol | p.o. | 10 | ML | 59,19 | K |
| 516 | V08AA | rozpustné nefrotropní hyperosmolární RTG kontrastní látky | parent. | ||||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 516.1 | V08AA01 | kyselina diatrizoová | parent. | 10 | ML | 45,00 | K |
| 516.2 | V08AA03 | iodamid (koncentrace 300 mg l/ml) | parent. | 10 | ML | 41,06 | K |
| 516.3 | V08AA03 | iodamid (koncentrace 380 mg l/ml) | parent. | 10 | ML | 44,97 | K |
| 516.4 | V08AA03 | iodamid (koncentrace 410 mg l/ml) | parent. | 10 | ML | 87,40 | K |
| 516.5 | V08AA05 | kyselina ioxitalamová (koncentrace 300 mg l/ml) | parent. | 10 | ML | 54,73 | K |
| 92350 | TELEBRIX N 380 | inj 6x20ml | LEX | CZ | |||
| 516.6 | V08AA05 | kyselina ioxitalamová (koncentrace 350 mg l/ml a více) | parent. | 10 | ML | 66,00 | K |
| 517 | V08AB | rozpustné nefrotropní nízkoosmolání RTG kontrastní látky | parent. | K | |||
| --- | --- | --- | --- | --- | --- | --- | --- |
Vyšetření iotrolanem ordinuje rentgenolog:
- a) pro intrathekální podání,
- b) v ostatních případech po předchozím schválení revizním lékařem.
| 517.1 | V08AB02 | iohexol (koncentrace 180 mg l/ml, do 15 ml v ampuli včetně) | parent. | 10 | ML | 184,90 | K |
|---|---|---|---|---|---|---|---|
| 517.2 | V08AB02 | iohexol (koncentrace 240 mg l/ml, nad 15 do 30 ml v ampuli včetně) | parent. | 10 | ML | 159,40 | K |
| 517.3 | V08AB02 | iohexol (koncentrace 240 mg l/ml, do 15 ml v jedné ampuli včetně) | parent. | 10 | ML | 220,90 | K |
| 517.4 | V08AB02 | iohexol (koncentrace 240 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 122,70 | K |
| 517.5 | V08AB02 | iohexol (koncentrace 300 mg l/ml, nad 15 do 30 ml v ampuli včetně) | parent. | 10 | ML | 185,50 | K |
| 517.6 | V08AB02 | iohexol (koncentrace 300 mg l/ml, do 15 ml v ampuli včetně) | parent. | 10 | ML | 256,70 | K |
| 517.7 | V08AB02 | iohexol (koncentrace 300 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 142,65 | K |
| 517.8 | V08AB02 | iohexol (koncentrace 350 mg l/ml, do 30 ml v ampuli včetně) | parent. | 10 | ML | 207,20 | K |
| 517.9 | V08AB02 | iohexol (koncentrace 350 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 159,40 | K |
| 517.10 | V08AB03 | kyselina ioxagliková (koncentrace 320 mg l/ml, do 30 ml v ampuli včetně) | parent. | 10 | ML | 236,91 | K |
| 59545 | HEXABRIX 320 | inj sol 25x50ml | GUT | F | |||
| 59544 | HEXABRIX 320 | inj sol 1x50ml | GUT | F | |||
| 517.11 | V08AB03 | kyselina ioxagliková (koncentrace 320 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 186,90 | K |
| 517.12 | V08AB04 | iopamidol (koncentrace 200 mg l/ml, do 15 ml v ampuli včetně) | parent. | 10 | ML | 242,54 | K |
| 517.13 | V08AB04 | iopamidol (koncentrace 300 mg l/ml, do 15 ml v ampuli včetně) | parent. | 10 | ML | 299,78 | K |
| 517.14 | V08AB04 | iopamidol (koncentrace 300 mg l/ml, nad 15 do 30 ml v ampuli včetně) | parent. | 10 | ML | 185,92 | K |
| 517.15 | V08AB04 | iopamidol (koncentrace 300 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 169,67 | K |
| 517.16 | V08AB04 | iopamidol (koncentrace 370 mg l/ml, do 15 ml v ampuli včetně) | parent. | 10 | ML | 365,98 | K |
| 517.17 | V08AB04 | iopamidol (koncentrace 370 mg l/ml, nad 15 do 30 ml v jedné ampuli včetně) | parent. | 10 | ML | 224,93 | K |
| 517.18 | V08AB04 | iopamidol (koncentrace 370 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 181,10 | K |
| 517.19 | V08AB05 | iopromid (koncentrace 240 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 122,70 | K |
| 517.20 | V08AB05 | iopromid (koncentrace 300 mg l/ml, do 30 ml v ampuli včetně) | parent. | 10 | ML | 185,40 | K |
| 517.21 | V08AB05 | iopromid (koncentrace 300 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 142,60 | K |
| 517.22 | V08AB05 | iopromid (koncentrace 370 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 165,80 | K |
| 517.23 | V08AB06 | iotrolan (koncentrace 240 mg l/ml, do 15 ml v ampuli včetně) | parent. | 10 | ML | 429,71 | K/P |
| 517.24 | V08AB06 | iotrolan (koncentrace 300 mg l/ml, do 15 ml v ampuli včetně) | parent. | 10 | ML | 534,28 | K/P |
| 517.25 | V08AB07 | ioversol (koncentrace 160 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 95,60 | K |
| 517.26 | V08AB07 | ioversol (koncentrace 240 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 122,70 | K |
| 517.27 | V08AB07 | ioversol (koncentrace 300 mg l/ml, do 15 ml v ampuli včetně) | parent. | 10 | ML | 256,70 | K |
| 517.28 | V08AB07 | ioversol (koncentrace 300 mg l/ml, nad 15 do 30 ml v ampuli včetně) | parent. | 10 | ML | 185,40 | K |
| 517.29 | V08AB07 | ioversol (koncentrace 300 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 142,65 | K |
| 517.30 | V08AB07 | ioversol (koncentrace 320 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 149,50 | K |
| 517.31 | V08AB07 | ioversol (koncentrace 350 mg l/ml, do 30 ml v ampuli včetně) | parent. | 10 | ML | 207,20 | K |
| 517.32 | V08AB07 | ioversol (koncentrace 350 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 159,42 | K |
| 517.33 | V08AB09 | iodixanol (koncentrace 150 mg l/ml, od 50 ml v jedné ampuli) | parent. | 10 | ML | 215,46 | K |
| 42405 | VISIPAQUE 150 MG l/ML | inj sol 10x50ml-amp | NRI | IRL | |||
| 84340 | VISIPAQUE 150MG l/ML | inj 6x200ml | NYI | N | |||
| 42401 | VISIPAQUE 150 MG l/ML | inj sol 10x100ml-pp | NRI | IRL | |||
| 42404 | VISIPAQUE 150 MG l/ML | inj sol 10x50ml-amp | NYI | N | |||
| 45114 | VISIPAQUE 150MG l/ML | inj 10x50ml | NRI | IRL | |||
| 42402 | VISIPAQUE 150 MG l/ML | inj sol 10x200ml-pp | NYI | N | |||
| 42400 | VISIPAQUE 150 MG l/ML | inj sol 10x100ml-pp | NYI | N | |||
| 42398 | VISIPAQUE 150 MG l/ML | inj sol 6x500ml-skl | NYI | N | |||
| 42399 | VISIPAQUE 150 MG l/ML | inj sol 6x500ml-skl | NRI | IRL | |||
| 84339 | VISIPAQUE 150MG l/ML | inj 10x50ml | NYI | N | |||
| 45115 | VISIPAQUE 150MG l/ML | inj 6x200ml | NRI | IRL | |||
| 42403 | VISIPAQUE 150 MG l/ML | inj sol 10x200ml-pp | NRI | IRL | |||
| 517.34 | V08AB09 | iodixanol (koncentrace 270 mg l/ml, do 30 ml včetně v jedné ampuli ) | parent. | 10 | ML | 336,60 | K |
| 42423 | VISIPAQUE 270 MG l/ML | inj sol 10x20ml-amp | NRI | IRL | |||
| 45118 | VISIPAQUE 270MG l/ML | inj 10x20ml | NRI | IRL | |||
| 42420 | VISIPAQUE 270 MG l/ML | inj sol 10x10ml-amp | NYI | N | |||
| 84341 | VISIPAQUE 270MG l/ML | inj 10x20ml | NYI | N | |||
| 42422 | VISIPAQUE 270 MG l/ML | inj sol 10x20ml-amp | NYI | N | |||
| 42421 | VISIPAQUE 270 MG l/ML | inj sol 10x10ml-amp | NRI | IRL | |||
| 517.35 | V08AB09 | iodixanol (koncentrace 270 mg l/ml, od 50 ml v jedné ampuli) | parent. | 10 | ML | 282,14 | K |
| 42409 | VISIPAQUE 270 MG l/ML | inj sol 10x75ml-pp | NRI | IRL | |||
| 84343 | VISIPAQUE 270MG l/ML | inj 10x100ml | NYI | N | |||
| 42424 | VISIPAQUE 270 MG l/ML | inj sol 10x40ml-amp | NYI | N | |||
| 84344 | VISIPAQUE 270MG I/ML | inj 6x200ml | NYI | N | |||
| 42425 | VISIPAQUE 270 MG I/ML | inj sol 10x40ml-amp | NRI | IRL | |||
| 45120 | VISIPAQUE 270MG I/ML | inj 10x100ml | NRI | IRL | |||
| 45119 | VISIPAQUE 270MG I/ML | inj 10x50ml | NRI | IRL | |||
| 42426 | VISIPAQUE 270 MG I/ML | inj sol 10x50ml-amp | NYI | N | |||
| 42427 | VISIPAQUE 270 MG I/ML | inj sol 10x50ml-amp | NRI | IRL | |||
| 45121 | VISIPAQUE 270MG I/ML | inj 6x200ml | NRI | IRL | |||
| 42415 | VISIPAQUE 270 MG l/ML | inj sol 10x175ml-pp | NRI | IRL | |||
| 42410 | VISIPAQUE 270 MG I/ML | inj sol 10x100ml-pp | NYI | N | |||
| 42411 | VISIPAQUE 270 MG I/ML | inj sol 10x100ml-pp | NRI | IRL | |||
| 42412 | VISIPAQUE 270 MG I/ML | inj sol 10x150ml-pp | NYI | N | |||
| 84342 | VISIPAQUE 270MG I/ML | inj 10x50ml | NYI | N | |||
| 42414 | VISIPAQUE 270 MG I/ML | inj sol 10x175ml-pp | NYI | N | |||
| 42416 | VISIPAQUE 270 MG I/ML | inj sol 10x200ml-pp | NYI | N | |||
| 42417 | VISIPAQUE 270 MG I/ML | inj sol 10x200ml-pp | NRI | IRL | |||
| 42418 | VISIPAQUE 270 MG I/ML | inj sol 6x500ml-pp | NYI | N | |||
| 42419 | VISIPAQUE 270 MG I/ML | inj sol 6x500ml-pp | NRI | IRL | |||
| 42408 | VISIPAQUE 270 MG I/ML | inj sol 10x75ml-pp | NYI | N | |||
| 42407 | VISIPAQUE 270 MG I/ML | inj sol 6x500ml-skl | NRI | IRL | |||
| 42406 | VISIPAQUE 270 MG I/ML | inj sol 6x500ml-skl | NYI | N | |||
| 42413 | VISIPAQUE 270 MG I/ML | inj sol 10x150ml-pp | NRI | IRL | |||
| 517.36 | V08AB09 | iodixanol (koncentrace 320 mg l/ml, do 30 ml včetně v jedné ampuli) | parent. | 10 | ML | 357,46 | K |
| 42442 | VISIPAQUE 320 MG I/ML | inj sol 10x10ml-amp | NYI | N | |||
| 42444 | VISIPAQUE 320 MG I/ML | inj sol 10x20ml-amp | NYI | N | |||
| 45122 | VISIPAQUE 320MG I/ML | inj 10x20ml | NRI | IRL | |||
| 84345 | VISIPAQUE 320MG I/ML | inj 10x20ml | NYI | N | |||
| 42445 | VISIPAQUE 320 MG I/ML | inj sol 10x20ml-amp | NRI | IRL | |||
| 42443 | VISIPAQUE 320 MG I/ML | inj sol 10x10ml-amp | NRI | IRL | |||
| 517.37 | V08AB09 | iodixanol (koncentrace 320 mg l/ml, od 50 ml v jedné ampuli) | parent. | 10 | ML | 287,25 | K |
| 42432 | VISIPAQUE 320 MG I/ML | inj sol 10x100ml-pp | NYI | N | |||
| 42439 | VISIPAQUE 320 MG I/ML | inj sol 10x200ml-pp | NRI | IRL | |||
| 45125 | VISIPAQUE 320MG I/ML | inj 6x200ml | NRI | IRL | |||
| 45124 | VISIPAQUE 320MG I/ML | inj 10x100ml | NRI | IRL | |||
| 45123 | VISIPAQUE 320MG I/ML | inj 10x50ml | NRI | IRL | |||
| 42449 | VISIPAQUE 320 MG I/ML | inj sol 10x50ml-amp | NRI | IRL | |||
| 42448 | VISIPAQUE 320 MG I/ML | inj sol 10x50ml-amp | NYI | N | |||
| 42447 | VISIPAQUE 320 MG I/ML | inj sol 10x40ml-amp | NRI | IRL | |||
| 42446 | VISIPAQUE 320 MG I/ML | inj sol 10x40ml-amp | NYI | N | |||
| 42430 | VISIPAQUE 320 MG I/ML | inj sol 10x75ml-pp | NYI | N | |||
| 42440 | VISIPAQUE 320 MG I/ML | inj sol 6x500ml-pp | NYI | N | |||
| 84348 | VISIPAQUE 320MG I/ML | inj 6x200ml | NYI | N | |||
| 42438 | VISIPAQUE 320 MG I/ML | inj sol 10x200ml-pp | NYI | N | |||
| 42429 | VISIPAQUE 320 MG I/ML | inj sol 6x500ml-skl | NRI | IRL | |||
| 42436 | VISIPAQUE 320 MG I/ML | inj sol 10x175ml-pp | NYI | N | |||
| 42435 | VISIPAQUE 320 MG I/ML | inj sol 10x150ml-pp | NRI | IRL | |||
| 42434 | VISIPAQUE 320 MG I/ML | inj sol 10x150ml-pp | NYI | N | |||
| 42433 | VISIPAQUE 320 MG I/ML | inj sol 10x100ml-pp | NRI | IRL | |||
| 84347 | VISIPAQUE 320MG I/ML | inj 10x100ml | NYI | N | |||
| 42431 | VISIPAQUE 320 MG I/ML | inj sol 10x75ml-pp | NRI | IRL | |||
| 42437 | VISIPAQUE 320 MG I/ML | inj sol 10x175ml-pp | NRI | IRL | |||
| 84346 | VISIPAQUE 320MG l/ML | inj 10x50ml | NYI | N | |||
| 42441 | VISIPAQUE 320 MG l/ML | inj sol 6x500ml-pp | NRI | IRL | |||
| 42428 | VISIPAQUE 320 MG l/ML | inj sol 6x500ml-skl | NYI | N | |||
| 517.38 | V08AB10 | iomeprol (koncentrace 150 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 92,70 | K |
| 517.39 | V08AB10 | iomeprol (koncentrace 200 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 109,70 | K |
| 517.40 | V08AB10 | iomeprol (koncentrace 250 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 126,00 | K |
| 517.41 | V08AB10 | iomeprol (koncentrace 300 mg l/ml, do 30 ml v ampuli včetně) | parent. | 10 | ML | 185,50 | K |
| 517.42 | V08AB10 | iomeprol (koncentrace 300 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 142,65 | K |
| 517.43 | V08AB10 | iomeprol (koncentrace 350 mg l/ml, do 30 ml v ampuli včetně) | parent. | 10 | ML | 207,20 | K |
| 517.44 | V08AB10 | iomeprol (koncentrace 350 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 159,40 | K |
| 517.45 | V08AB10 | iomeprol (koncentrace 400 mg l/ml, do 30 ml v ampuli včetně) | parent. | 10 | ML | 228,70 | K |
| 517.46 | V08AB10 | iomeprol (koncentrace 400 mg l/ml, nad 50 ml v ampuli) | parent. | 10 | ML | 175,90 | K |
| 517.47 | V08AB11 | lobitridol (koncentrace 300 mg nad 50 ml v ampuli) | parent. | 10 | ML | 142,65 | K |
| 517.48 | V08AB11 | lobitridol (koncentrace 350 mg nad 50 ml v ampuli) | parent. | 10 | ML | 159,40 | K |
| 518 | V08AC | rozpustné hepatotropní RTG kontrastní látky | parent. | ||||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 518.1 | V08AC | kyselina iodoxamová (koncentrace 183 mg l/ml) | parent. | 10 | ML | 74,25 | K |
| 518.2 | V08AC | kyselina iodoxamová (koncentrace 45 mg l/ml) | parent. | 10 | ML | 37,39 | K |
| 518.3 | V08AC04 | adipiodon | parent. | 10 | ML | 39,35 | K |
| 519 | V08AD | nerozpustné RTG kontrastní látky | parent. | ||||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 519.1 | V08AD | iopydol + iopyron | parent. | 10 | ML | 300,70 | K |
| 519.2 | V08AD01 | ethylestery jodovaných mastných kyselin | parent. | 10 | ML | 462,54 | K |
| 59494 | LIPIODOL ULTRA-FLUIDE | inj 1x10ml/4.8gm i | GUT | F | |||
| 520 | V08BA | RTG kontrastní přípravky obsahující síran barnatý | p.o. | ||||
| 520.1 | V08BA01 | síran barnatý | p.o. | 100 | GM | 32,15 | K |
| 59062 | MICROPAQUE | sus 1x2000ml | DEF | F | |||
| 520.2 | V08BA01 | síran barnatý (lékové formy pro CT) | p.o. | 7.5 | GM | 147,52 | K |
| 62399 | E-Z-CAT | sus 1x225ml | EZE | USA | |||
| 46675 | MICROPAQUE CT | sus 1x2000ml/100gm | DEF | F | |||
| 78269 | E-Z-CAT | sus 1x225ml | EZE | CND | |||
| 520.3 | V08BA01 | RTG kontrastní přípravky obsahující síran barnatý (lékové formy kolon) | p.rect. | 100 | GM | 45,00 | K |
| 520.4 | V08BA01 | síran barnatý (lékové formy pasty) | p.o. | 100 | GM | 94,58 | K |
| 520.5 | V08BA01 | síran barnatý (lékové formy HD) | p.o. | 100 | GM | 36,73 | K |
| 59063 | MICROPAQUE H.D. ORAL | plv 1x416gm | DEF | F | |||
| 521 | V08CA | paramagnetické kontrastní látky | parent. | ||||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 521.1 | V08CA01 | dimeglumin gadopentetat (do 10 ml v 1 ampuli včetně) | parent. | 10 | ML | 1582,80 | K |
| 521.2 | V08CA01 | dimeglumin gadopentetat (nad 10 ml v 1 ampuli) | parent. | 10 | ML | 1472,10 | K |
| 521.3 | V08CA02 | meglumin gadoterat do 10 ml v jedné ampuli včetně | parent. | 10 | ML | 1582,80 | K |
| 521.4 | V08CA02 | meglumin gadoterat nad 10 ml v jedné ampuli | parent. | 10 | ML | 1472,10 | K |
| 521.5 | V08CA03 | gadodiamid (do 10 ml v 1 ampuli včetně) | parent. | 10 | ML | 1582,80 | K |
| 521.6 | V08CA03 | gadodiamid (nad 10 ml v 1 ampuli) | parent. | 10 | ML | 1472,10 | K |
| 521.7 | V08CA04 | gadoteridol (do 10 ml v 1 ampuli včetně) | parent. | 10 | ML | 1582,80 | K |
| 521.8 | V08CA04 | gadoteridol (nad 10 ml v 1 ampuli) | parent. | 10 | ML | 1472,10 | K |
| 521.9 | V08CA05 | mangafodipir | parent. | 10 | ML | 916,70 | K |
| 521.10 | V08CA08 | dimeglumin gadobenat (do 10 ml v 1 ampuli včetně) | parent. | 10 | ML | 1582,80 | K |
| 521.11 | V08CA08 | dimeglumin gadobenat (nad 10 ml v 1 ampuli) | parent. | 10 | ML | 1472,10 | K |
| 521.12 | V08CA09 | gadobutrol, koncentrace do 0,5 mmol/l včetně | parent. | 10 | ML | 1472,10 | K |
| 521.13 | V08CA09 | gadobutrol, koncentrace nad 0,5 mmol/l | parent. | 10 | ML | 2208,10 | K |
| 521.14 | V08CB03 | oxid železa, nanočástice, s obsahem do 0,9 ml včetně | parent. | 1 | DF | 5780,78 | H |
| 521.15 | V08CB03 | oxid železa, nanočástice, s obsahem nad 0,9 ml | parent. | 1 | DF | 6700,00 | H |
| 521.16 | V08DA01 | mikročástice albuminu s oktafluoropanem | parent. | 1 | DF | 2857,50 | H |
| 521.17 | V08DA02 | mikročástice galaktózy | parent. | 1 | GM | 914,00 | H |
Čl. II
Tato vyhláška nabývá účinnosti dnem 1. července 2003.
Ministryně:
MUDr. Součková v. r.
Čtení tohoto dokumentu nenahrazuje čtení příslušného vydání Sbírky zákonů. Neneseme odpovědnost za případné nepřesnosti vyplývající z převodu originálu do tohoto formátu.
Tento text je zveřejněn za vlastních podmínek opětovného použití zdroje e-Sbírka, nikoli pod licencí Legalize ani pod licencí volného díla.
e-Sbírka
volné dílo (úřední díla podle § 3 písm. a) zákona č. 121/2000 Sb., autorského zákona)